ovarian cancer

Showing 15 posts of 54 posts found.

J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products

November 4, 2020
Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc

Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …


Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer

July 13, 2020
Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq

Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …


Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer

May 11, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …


Women who take statins could be less likely to develop ovarian cancer, study finds

February 19, 2020
Research and Development, Sales and Marketing Cancer, Cancer Research UK, cholesterol, ovarian cancer, statins

A study by Cancer Research UK has found that women who take statins, drugs that lower cholesterol, are less likely …


Jury orders Johnson & Johnson to pay $750 million in latest baby powder case

February 7, 2020
Medical Communications J&J, JJ, Johnson & Johnson, ovarian cancer, talc, talc powder

Johnson & Johnson have been ordered to pay by a jury $750 million to four plaintiffs over the company’s baby …

NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases

December 2, 2019
Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma

NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …


Ovarian cancer market set to smash $6.7 billion by 2025

October 28, 2019
Sales and Marketing Cancer, GlobalData, ovarian cancer, pharma

New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound …

Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …


GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …


Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …


EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer

June 18, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …


ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019
Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …


AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer

April 29, 2019
Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …

Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial

March 20, 2019
Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer

Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …


GSK acquires oncology firm Tesaro for $5.1 billion

January 23, 2019
Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer

British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …

Latest content